Jefferies Global Healthcare Conference New York 2014
|
|
- Amber Morgan
- 5 years ago
- Views:
Transcription
1 Jefferies Global Healthcare Conference New York 2014
2 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements" and are based on Management s current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the success of the Company s research strategy; the applicability of discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company s potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payers; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. Therefore those statements involve risks and uncertainties beyond the Company's control and actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forwardlooking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law. 2
3 Corporate Overview: Zeltia S.A. Focused on Oncology Leader in developing and commercializing marine-derived oncology drugs Non-core businesses Molecular diagnostics; targeted RNAi agents with no systemic administration; and consumer chemicals Key Facts Ticker: ZEL SM (MEC) Market Cap*: 622 million 2013 Total Income: EBITDA: 23.8 * As of 30th May 2014 Oncology Non-core businesses Air fresheners, Insecticides Paintings, wood treatment 3
4 Corporate Overview: Unique R&D Capabilities The Sea World leader in development of marine-derived oncology compounds Library of 150,000 marine samples Excellent source of biological material for drug discovery 4
5 Fully Integrated: Drug Development Capabilities IP and Trademarks Commercialization Clinical Trials Production Keep last steps of purification or synthesis within PharmaMar Broad patent coverage License US & RoW Keep EU rights Preclinical Testing International clinical development in Europe, US & Canada Screening and Optimization Medicinal Chemistry Marine Expeditions R4O OR 5 OR 6 OR7 Evaluate New Compounds New chemical scaffolds & New MoAs R 3O R 2O Synthesis of identified NCEs Activity improvement R 1 N R 8 O O Build a Library (150,000 samples) 5
6 Pipeline: Targeting Multiple Indications Clinical Program / Indication Partners Phase I Phase II Phase III Yondelis Soft Tissue Sarcoma 2 nd /3 rd line; EU/others R/R ovarian cancer (Yondelis +Doxil); EU/others Soft Tissue Sarcoma 2nd/3rd line; US R/R ovarian cancer (Yondelis +Doxil); US Soft Tissue Sarcoma 2 nd /3 rd line; Japan (pivotal) Aplidin R/R multiple myeloma R/R T-cell lymphoma (Pivotal) R/R multiple myeloma Combo Bortezomib PM1183 Platinum Resistant ovarian cancer BRCA 1/2 associated breast cancer NSCLC Endometrial cancer Acute leukemia PM184 Combo Studies Registration Application Market 6
7 Yondelis : Commercial Success Validates Marine Biotechnology Platform Main Oncology Markets Europe 30% US 45% Japan 9% Source: IMS 2013 Yondelis approved in >75 countries for advanced STS and, in combination with Doxil / Caelyx, for relapsed platinum-sensitive ovarian cancer Yondelis partnered with Johnson & Johnson and TAIHO Pharmaceuticals 7
8 PFS Probability (%) Yondelis: Positive Survival Trend and Superior PFS (Taiho, Japan) Months Takahashi et al. ASCO
9 OS Probability (%) Yondelis: Positive Survival Trend and Superior OS (Taiho, Japan) N Median OS 95% CI Trabectedin BSC HR= 0.38 (95% CI [0.16, 0.91] ) P value = Months Takahashi et al. ASCO
10 Aplidin: Marine Compound Aplidium albicans Plitidepsin Synthetic cyclic depsipeptide isolated from the marine tunicate Aplidium albicans First in class drug with a new and different mechanism of action compared to current drugs used in the clinic The potential target is the proto-oncogene eef1α 10
11 Aplidin : ADMYRE (Phase III) III) Relapsed/Refractory Multiple Multiple Myeloma Myeloma Design: Phase III, randomized (2:1), multicentre, after 3 but no more than 6 lines of chemotherapy, 2-parallel group Objective: Progression-Free Survival (PFS) Primary Endpoint: Increase of 60% in PFS in Arm A Number of patients: 250 Arms: A: Aplidin in combination with Dexamethasone (n=167) B: Dexamethasone alone (n=83) Interim analysis performed after the inclusion of 79 patients Phase III IDMC Positive Recommendation (December 2012) RR 30% Well tolerated Estimated date of final recruitment 2H14 Centres: America, Europe, Asia, Australia, New Zealand 11
12 PM1183: Potent Oncology Compound PM1183, a second generation Yondelis, with activity in new indications Yondelis Protein-binding moiety: Free to interact PM1183 M e O H O M e O O O A c O O O N H S H N H O O H N O C H 3 O N H O A c O O O N H S H N H O O H N O C H 3 DNA-binding moiety: Binds to minor groove and bends DNA 12
13 PM1183: Favourable PK Profile vs. Yondelis PM1183 is administered as a 1h infusion versus 24h infusion with Yondelis PM1183, 4 mg/m 2 Yondelis, 1 mg/m 2 PM1183 is well-tolerated with peripheral administration, while Yondelis is administered via central catheter PM1183 vs. Yondelis AUC HL PM Yondelis x tolerated dose 15x exposure at RD Less cumulative toxicity, better handling 13
14 PM1183: Compelling Activity in Platinum-Resistant Ovarian Cancer Phase IIb Results* PM1183 Topotecan CR 1 (3%) 0 (0%) PR 9 (27%) 0 (0%) SD 17 (52%) 8 (50%) PD 6 (18%) 8 (50%) ORR 10 (30.3%) 0 (0%) DCR 27 (82%) 8 (50%) Total * Poveda et al. ESMO
15 PFS Cumulative probability PM1183: Positive Survival Trend and Superior PFS Platinum-Resistant Stage II 1.7 mo. 5.7 mo. PM01183 (N=17 C=4) Topotecan (N=16 C=2) Censored HR: 0.30 (95%CI ) p=0.005* Time (months) *log-rank test Poveda et al. ASCO
16 OS Cumulative probability PM1183: Positive Survival Trend and Superior OS Platinum-Resistant Stage II Not reached 8.3 mo Time (months) PM01183 (N=17 C=9) Topotecan (N=16 C=4) Censored HR: 0.40 (95%CI ) p=0.039* *log-rank test Poveda et al. ASCO
17 PM1183: Design of Metastatic Breast Cancer Phase IIb Study PM1183 Single Agent Stage I 4 pts with ORR Arm A Mut-BRCA1/2 (n=20) Stage I I Arm B Unknown status (n=30) 3 pts with ORR + (n=33 patients) + (n=34 patients) Primary Endpoint: Overall Response Rate (RECIST v1.1) Centres USA & Spain: Investigators: Massachusetts General Hospital Dr. Steven Jay Isakoff Dana-Farber Cancer Institute Dr. Judy Garber Beth Israel Deaconess Medical Center Dr. Nadine Tung Hospital Vall d Hebrón Dr. Judith Balmaña Hospital Clínico Universitario de Valencia Dr. Ana Lluch 17
18 PM1183: Phase IIb PM1183/Gemcitabine combo in NSCLC PM1183/Gemcitabine combo EGFR-non mutated advanced NSCLC (1 prior line) n=120 Stratified by histology: squamous vs. non-squamous PM1183/ GEM n=40 PM1183 alone n=40 Docetaxel (ctrl. arm) n=40 Primary endpoint: PFS at 4 months Secondary endpoints: Safety Response rate PFS/ Overall Survival Pharmacogenomics 18
19 Evaluable patients (n=40) PM1183: Phase I Gemcitabine Combo (5%) 4(21%) 7(37%) 7% NSCLC 1(13%) 4(50%) 3% Pancreas RD is 800 mg/m2 Gem mg flat dose PM1183 both D1and D8 q3wk 1(17%) 4(67%) 1% Breast 2(40%) 1 (20%) 2% Ovarian 2 (100%) Mesothelioma RECIST v1.1 CR PR SD PD Excellent chronic tolerance (6+ cycles in 32% of patients) A phase II combination trial in NSCLC to start in 3Q
20 Evaluable patients (n=42) PM1183: Phase I Doxorubicin Combo. RECIST v1.1 CR PR SD PD (42%) 1(11%) 7 6 1(8%) 4(44%) 5 4 1(20%) (100%) Ovarian (n=1) 1(33%) 1(33%) 1(33%) Endometrial (n=3) 1(33%) 1(33%) 1(33%) Breast (n=3) 2(50%) 2(50%) NET (n=4) 6(50%) SCLC (n=12) 4(44%) STS (n=9) 2(40%) 2(40%) Bladder (n=5) 4(80%) 1(20%) Gastric/HCC (n=5) CR, complete response; HCC, hepatocellular carcinoma; NET, neuroendocrine tumours; PD, progressive disease; PR, partial response; pts, patients; SCLC, small-cell lung cancer; SD, stable disease; STS, soft-tissue sarcoma Excellent chronic tolerance (6+ cycles in 34 % of patients) Calvo et al. ESMO
21 Zeltia Group Financial Profile: Improving Total Revenues Total Income (Euro million) ,7 51, ,7 Start of Caelyx Shortage in EU: 3Q ,9 79,4 80,6 End of Caelyx shortage in EU: 2Q ,5 22,8 72,4 79,1 71,2 73,2 71,2 64,7 61, Consumer Chemicals Biopharmaceutical Other Income 21
22 Driving Profitability through Revenue Diversification Net EBITDA (Euro million) 40,0 30,0 + 13,2 + 20,4 4,9 + 23,8 3,8 20,0 10,0 11,3 10,0 8,5 13,1 22,8 26,2 0,0-5,9-8,4-7,3-6,3-10,0-20,0-21,0-6,4-8,0-3,9-30, Biotechnology Consumer Chemicals Other 22
23 Key Upcoming Events* PM1183 Start Phase III Pivotal Trial Endometrial C. Aplidin Final Recruitment Phase III trial Multiple Myeloma PM1183 Start Phase III trial Resistant Ovarian C. PM1183 Start Phase II Pivotal trial SCLC Yondelis: Expected New Approvals J&J Milestone Payment: USD 25mn Yondelis: Expected dossier filing STS Japan Yondelis: Expected dossier filing STS US J&J Milestone Payment Taiho Milestone Payment * Estimated dates 23
24 Thank you
CORPORATE PRESENTATION 2015
CORPORATE PRESENTATION 2015 DISCLAIMER This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 This document includes only summary information and is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management
More informationCorporate Presentation. March 2018
Corporate Presentation March 2018 This document includes only summary information and is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management
More informationSe adjunta presentación corporativa en inglés que estará disponible también en la página web de la Compañía
Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados C/Edison núm. 4 28006 Madrid Colmenar Viejo (Madrid), a 9 de enero de 2018 De conformidad con lo previsto en el artículo 228
More informationCorporate Presentation. June 2018
Corporate Presentation June 2018 This document includes only summary information and is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationHighlights of these abstracts are presented below:
PharmaMar announces the presentation of 15 abstracts on Yondelis and Aplidin at the 46 th annual meeting of the American Society of Clinical Oncology (ASCO) Madrid, 9 June 2010: PharmaMar SA (Grupo Zeltia,
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationDisclaimer. September 2018
September 2018 September 2018 Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationDisclaimer. September 2018
September 2018 September 2018 Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity,
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationPharmaMar shows new clinical data with Yondelis in different sarcoma subtypes at CTOS 2016
PharmaMar shows new clinical data with Yondelis in different sarcoma subtypes at CTOS 2016 Madrid, November 10 th, 2016.- Within the framework of the 21 st Annual Meeting of the Connective Tissue Oncology
More informationREPORT AT 30 JUNE 2015
REPORT AT 30 JUNE 2015 Madrid, 28 July 2015 1H15 HIGHLIGHTS Corporate Group net revenues amounted to 84.4 million euro (+7.8%). Of that figure, 43.6 million euro (+11.4%) were from Yondelis (40.3 million
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationtrabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal
trabectedin, 0.25 and 1mg powder for concentrate for solution for infusion (Yondelis ) SMC No. (452/08) Pharma Mar S.A. Sociedad Unipersonal 08 October 2010 The Scottish Medicines Consortium (SMC) has
More informationTivantinib Overview April 2016
Tivantinib Overview April 2016 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationFOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE. Thursday, February 7, 2019
FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS UPDATE Thursday, February 7, 2019 Today s Speakers Overview and Key Highlights Clay Siegall, President & CEO Financial Results and Guidance
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationSe adjunta presentación corporativa en inglés que estará disponible también en la página web de la Compañía
Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados C/Edison núm. 4 28006 Madrid Colmenar Viejo (Madrid), a 12 de junio de 2018 De conformidad con lo previsto en el artículo 228
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationDisclaimer. December 2018
December 2018 December 2018 Disclaimer This presentation contains forward-looking statements that include information about possible or assumed future results of the business, financial condition, liquidity,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationGenómica has received business license enabling it to operate in China
REPORT AT 31 MARCH 2018 Madrid, 26 April 2018 1Q18 MILESTONES Corporate Group revenues amounted to 44.7 million in the first quarter of 2018, compared with 45.5 million in the same period of 2017. A shift
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationForward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including statements related to Seattle Genetics corporate priorities, financial guidance and anticipated upcoming activities,
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationCowen Annual Healthcare Conference. March 2018
Cowen Annual Healthcare Conference March 2018 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCompany presentation. Jefferies Global Healthcare Conference New York, June 6, Claudio Bordignon Chairman and CEO
Company presentation Jefferies Global Healthcare Conference New York, June 6, 2013 Claudio Bordignon Chairman and CEO Forward-looking statements The presentation contains certain forward-looking statements.
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationINTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationThe Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationB I ABOUT BI DISEASE AREA & MECHANISM OF ACTION. For journalists outside UK/US/Canada only B A C K G R O U N D E R
For journalists outside UK/US/Canada only B I 1 4 8 2 6 9 4 1. About BI 1482694 2. Disease area & mechanism of action 3. Development status 4. Data overview 1. ABOUT BI 1482694 BI 1482694* (HM61713**)
More informationA Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationREPORT AS OF 31 DECEMBER 2018
REPORT AS OF 31 DECEMBER 2018 Madrid, 28 February 2019 MILESTONES IN 2018 Corporate Group revenues amounted to 162.6 million in 2018, compared with 158.9 million in 2017 (+2%). As part of PharmaMar's strategy
More informationDiagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015
Diagnostics for the early detection and prevention of colon cancer Leerink Swann Global Health Care Conference February 2015 Safe Harbor Statement Certain statements made in this news release contain forward-looking
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More information